 Insulin Glargine
"Insulin Glargine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.
| Descriptor ID |
D000069036
|
| MeSH Number(s) |
D06.472.699.587.200.300.100 D12.644.548.586.200.300.100
|
| Concept/Terms |
Insulin Glargine- Insulin Glargine
- Glargine, Insulin
- A21-Gly-B31-Arg-B32-Arg-insulin
- A21 Gly B31 Arg B32 Arg insulin
- Insulin, Glycyl(A21)-Arginyl(B31,B32)
- Glargine
- Insulin, Gly(A21)-Arg(B31,B32)
Lantus- Lantus
- Lantus Solostar
- Solostar, Lantus
HOE 901- HOE 901
- 901, HOE
- HOE-901
- HOE901
|
Below are MeSH descriptors whose meaning is more general than "Insulin Glargine".
Below are MeSH descriptors whose meaning is more specific than "Insulin Glargine".
This graph shows the total number of publications written about "Insulin Glargine" by people in this website by year, and whether "Insulin Glargine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 4 | 4 | | 2005 | 0 | 3 | 3 | | 2008 | 0 | 2 | 2 | | 2009 | 0 | 4 | 4 | | 2010 | 0 | 3 | 3 | | 2011 | 0 | 2 | 2 | | 2012 | 0 | 2 | 2 | | 2013 | 0 | 2 | 2 | | 2014 | 2 | 1 | 3 | | 2015 | 1 | 0 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 2 | 2 | 4 | | 2018 | 3 | 2 | 5 | | 2019 | 2 | 2 | 4 | | 2020 | 1 | 4 | 5 | | 2021 | 1 | 2 | 3 | | 2022 | 0 | 4 | 4 | | 2023 | 0 | 1 | 1 | | 2024 | 1 | 2 | 3 | | 2025 | 4 | 1 | 5 | | 2026 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Insulin Glargine" by people in Profiles.
-
Connery L, Rosenstock J, Rasouli N, Cheng AYY, Liebl A, Wang Q, Pires V, Knights A, Davidson MB, Child CJ. Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed-Dose Titration of Weekly Insulin Efsitora in Insulin-Naïve Type 2 Diabetes. Diabetes Obes Metab. 2026 Jul; 28(7):6217-6224.
-
Kahn SE, Tripputi M, Lachin JM, Balasubramanyam A, Banerji MA, Barzilay J, Cohen RM, Garvey WT, Gramzinski MR, Rasouli N, Rhee M, Seegmiller JC, Singh V, Sivitz WI, Steffes MW, Utzschneider K, DeFronzo RA. Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2026 Feb 01; 49(2):325-334.
-
Sarwal A, Singh R, Wei G, Shen J, Nevers M, Hartsell SE, Derington CG, Takyi A, Chakravartula AR, Katkam N, Boucher RE, Drakos SG, Greene T, Beddhu S. Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes. Diabetes Obes Metab. 2025 Oct; 27(10):5865-5877.
-
Utzschneider KM, Tripputi M, Butera NM, Mari A, Rosin SP, Banerji MA, Bergenstal RM, Brown N, Carlson AL, DeFronzo RA, Gramzinski MR, Harindhanavudhi T, Kozedub A, Sivitz WI, Steffes MW, Balasubramanyam A, Rasouli N. Differential Treatment Effects on ß-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2025 Apr 01; 48(4):623-631.
-
Shah VN, Dex T, Meneghini L, Rodrigues A, Polonsky WH. Treatment satisfaction and time in range after 16?weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes. Diabetes Obes Metab. 2025 May; 27(5):2523-2530.
-
Frías JP, Ratzki-Leewing A, Dex T, Meneghini L, Rodrigues A, Shah VN. Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes. Diabetes Obes Metab. 2025 Apr; 27(4):2173-2182.
-
Shen J, Sarwal A, Singh R, Hartsell SE, Wei G, Nevers M, Christensen JC, Takyi A, Katkam N, Derington CG, Deshmukh VG, Boucher RE, Drakos SG, Greene T, Beddhu S. Comparative effectiveness of insulin glargine, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in veterans with type 2 diabetes. Diabetes Obes Metab. 2025 Apr; 27(4):2120-2130.
-
Ohman-Hanson R, Alonso GT, Pyle L, McDonough R, Clements M. Management of diabetic ketoacidosis in children: Does early insulin glargine help improve outcomes? J Diabetes. 2024 Aug; 16(8):e13597.
-
Hollander PA, Krause-Steinrauf H, Butera NM, Kazemi EJ, Ahmann AJ, Fattaleh BN, Johnson ML, Killean T, Lagari VS, Larkin ME, Legowski EA, Rasouli N, Willis HJ, Martin CL. The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2024 Apr 01; 47(4):638-645.
-
Rasouli N, Younes N, Ghosh A, Albu J, Cohen RM, DeFronzo RA, Diaz E, Sayyed Kassem L, Luchsinger JA, McGill JB, Sivitz WI, Tamborlane WV, Utzschneider KM, Kahn SE. Longitudinal Effects of Glucose-Lowering Medications on ß-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial. Diabetes Care. 2024 Apr 01; 47(4):580-588.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|